Sponsor Check › Person
Related person on Form D filings · address states as listed: MA, NJ · listed May 17, 2011 → Dec 4, 2025
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:55 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:55 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:55 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
0 of 21 offerings report sales commissions; 0 report finder's fees; 0 report proceeds to related persons.
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Dec 4, 2025 D File 021-565748 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 14, 2025 D File 021-560739 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 5, 2024 D File 021-531177 | $0 | $0 | $0 An Affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Jan 17, 2024 D File 021-502717 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 19, 2022 D/A File 021-433414 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 3, 2022 D File 021-435762 | $0 | $0 | $0 An Affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Oct 1, 2021 D File 021-415392 | $0 | $0 | $0 An Affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Sep 17, 2021 D File 021-413815 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 6, 2021 D File 021-398517 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 26, 2021 D File 021-390683 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 21, 2021 D File 021-387002 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 14, 2020 D File 021-373292 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 4, 2020 D File 021-368325 | $0 | $0 | $0 An Affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Mar 27, 2020 D File 021-363863 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 2, 2019 D/A File 021-326809 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 31, 2018 D File 021-304462 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 30, 2017 D File 021-289898 | $0 | $0 | $0 An Affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Dec 18, 2014 D File 021-230375 | $0 | $0 | $0 An Affiliate of the General Partner will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Apr 17, 2014 D/A File 021-181765 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 24, 2012 D/A File 021-163669 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 17, 2011 D File 021-159952 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Triana Biomedicines, Inc. | Director | Dec 4, 2025 | D | $120,061,960 similar: $1,694,259–$16,000,000 | $120,061,960 | 20 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Affinia Therapeutics Inc. | Director | Oct 14, 2025 | D | $45,000,000 similar: $500,000–$7,000,000 | $13,268,335 | 20 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Atlas Venture Fund XIV, L.P. group: Atlas Venture | Executive Officer Member of the sole member of the GPLLC | Dec 5, 2024 | D | $450,000,000 similar: $155,000–$5,250,000 | $450,000,000 | 84 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Comanche Biopharma Corp. | Director | Jan 17, 2024 | D | $75,000,000 similar: $1,694,259–$16,000,000 | $37,500,000 | 7 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Triana Biomedicines, Inc. | Director | Apr 19, 2022 | D/A | $85,100,014 similar: $1,694,259–$16,000,000 | $42,550,007 | 14 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Atlas Venture Fund XIII, L.P. group: Atlas Venture | Executive Officer Member of the sole member of the GPLLC | Mar 3, 2022 | D | $450,000,000 similar: $155,000–$5,250,000 | $450,000,000 | 87 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Triana Biomedicines, Inc. | Director | Feb 11, 2022 | D | $80,000,016 similar: $1,694,259–$16,000,000 | $34,800,008 | 12 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Atlas Venture Opportunity Fund II, L.P. group: Atlas Venture | Executive Officer Member of the sole member of the GPLLC | Oct 1, 2021 | D | $300,000,000 similar: $155,000–$5,250,000 | $300,000,000 | 69 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Triana Biomedicines, Inc. | Director | Sep 17, 2021 | D | $10,000,000 similar: $1,694,259–$16,000,000 | $10,000,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Affinia Therapeutics Inc. | Director | May 6, 2021 | D | $109,999,955 similar: $500,000–$7,000,000 | $109,999,955 | 22 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Xilio Therapeutics, Inc. | Director | Feb 26, 2021 | D | $94,999,989 similar: $2,000,000–$19,999,994 | $94,999,989 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Xilio Therapeutics, Inc. | Director | Jan 21, 2021 | D | $50,249,990 similar: $2,000,000–$19,999,994 | $50,249,990 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Aerovate Therapeutics, Inc. | Director | Aug 14, 2020 | D | $75,818,727 similar: $1,694,259–$16,000,000 | $75,818,727 | 9 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Atlas Venture Fund XII, L.P. group: Atlas Venture | Executive Officer Member of the sole member of the GPLLC | Jun 4, 2020 | D | $400,000,000 similar: $155,000–$5,250,000 | $400,000,000 | 85 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Affinia Therapeutics Inc. | Director | Mar 27, 2020 | D | $68,522,920 similar: $500,000–$7,000,000 | $38,522,942 | 16 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Atlas Venture Opportunity Fund I, L.P. group: Atlas Venture | Executive Officer Member of the sole member of the GPLLC | Jan 2, 2019 | D/A | $250,000,000 similar: $155,000–$5,250,000 | $250,000,000 | 47 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Atlas Venture Opportunity Fund I, L.P. group: Atlas Venture | Executive Officer Member of the sole member of the GPLLC | Nov 29, 2018 | D | $200,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Akriveia Therapeutics, LLC group: Akriveia | Director | Jan 31, 2018 | D | $22,500,000 similar: $2,000,000–$19,999,994 | $3,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Atlas Venture Fund XI, L.P. group: Atlas Venture | Executive Officer Member of the sole member of the GPLLC | Jun 30, 2017 | D | $350,000,000 similar: $155,000–$5,250,000 | $350,000,000 | 70 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Atlas Venture Fund X, L.P. group: Atlas Venture | Executive Officer Member of the General Partner and the GPLLC | Dec 18, 2014 | D | $250,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Annovation BioPharma, Inc. group: Atlas Venture | Executive Officer, Director | Apr 17, 2014 | D/A | $11,000,201 similar: $1,694,259–$16,000,000 | $8,000,201 | 10 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Annovation BioPharma, Inc. group: Atlas Venture | Executive Officer, Director | Jul 25, 2012 | D | $8,000,201 | $2,022,701 | 10 | No minimum reported |
| EDGAR ↗ | Arteaus Therapeutics, LLC group: Atlas Venture | Executive Officer, Director | Jul 24, 2012 | D/A | $18,000,000 | $15,600,000 | 3 | No minimum reported |
| EDGAR ↗ | Arteaus Therapeutics, LLC group: Atlas Venture | Executive Officer, Director | Jul 29, 2011 | D | $18,000,000 | $3,600,000 | 3 | No minimum reported |
| EDGAR ↗ | Annovation BioPharma, Inc. group: Atlas Venture | Executive Officer | May 17, 2011 | D | $750,000 | $375,000 | 11 | No minimum reported |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); Other / 506(b) (18,678 filings); Pooled Investment Fund / 506(b) (83,801 filings); Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
People and management entities the issuers listed as related persons on the same Form D filings as David Grayzel. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when David Grayzel appears on a new Form D, or when a court case or SEC action is matched to them. See plans →